Cargando…

Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats

BACKGROUND: Credelio(TM) (lotilaner) is an oral ectoparasiticide from the isoxazoline class developed for the treatment of flea and tick infestations in cats. It is formulated as a pure S-enantiomer in flavoured chewable tablets. The pharmacokinetics of lotilaner were investigated after intravenous...

Descripción completa

Detalles Bibliográficos
Autores principales: Toutain, Céline E., Seewald, Wolfgang, Jung, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044034/
https://www.ncbi.nlm.nih.gov/pubmed/30001724
http://dx.doi.org/10.1186/s13071-018-2966-6
_version_ 1783339402368385024
author Toutain, Céline E.
Seewald, Wolfgang
Jung, Martin
author_facet Toutain, Céline E.
Seewald, Wolfgang
Jung, Martin
author_sort Toutain, Céline E.
collection PubMed
description BACKGROUND: Credelio(TM) (lotilaner) is an oral ectoparasiticide from the isoxazoline class developed for the treatment of flea and tick infestations in cats. It is formulated as a pure S-enantiomer in flavoured chewable tablets. The pharmacokinetics of lotilaner were investigated after intravenous or oral administration and under fed or fasted conditions in cats. Twenty-six adult cats were enrolled in a pharmacokinetic study evaluating either intravenous or oral administration of lotilaner. Following the oral administration at a dosage of 6 mg/kg, under fed or fasted conditions, or intravenous administration of 3 mg/kg, blood samples were collected up to 35 days after treatment. Lotilaner blood concentrations were measured using a validated liquid chromatography/tandem mass spectrometry method. Pharmacokinetic parameters were calculated by non-compartmental analysis. In addition, in vivo enantiomer stability of lotilaner was evaluated in a separate bioanalytical study. RESULTS: Following oral administration in fed cats, lotilaner was readily absorbed and peak blood concentrations reached within four hours. The terminal half-life was 33.6 days. Food enhanced the absorption, providing close to 100% oral bioavailability and reduced the inter-individual variability. Following intravenous administration, lotilaner had a low clearance of 0.13 l/kg/day, large volumes of distribution V(z) and V(ss) of 5.34 and 5.37 l/kg, respectively and a terminal half-life of 28.7 days. In addition, there was no in vivo racemization of lotilaner. CONCLUSIONS: The pharmacokinetic properties of lotilaner administered orally as a flavoured chewable tablet (Credelio(TM)) were studied in detail. With a T(max) of 4 h and a terminal half-life of 33.6 days under fed conditions, lotilaner provides a rapid onset of flea and tick killing activity with consistent and sustained efficacy for at least one month in cats. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-018-2966-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6044034
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60440342018-07-13 Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats Toutain, Céline E. Seewald, Wolfgang Jung, Martin Parasit Vectors Research BACKGROUND: Credelio(TM) (lotilaner) is an oral ectoparasiticide from the isoxazoline class developed for the treatment of flea and tick infestations in cats. It is formulated as a pure S-enantiomer in flavoured chewable tablets. The pharmacokinetics of lotilaner were investigated after intravenous or oral administration and under fed or fasted conditions in cats. Twenty-six adult cats were enrolled in a pharmacokinetic study evaluating either intravenous or oral administration of lotilaner. Following the oral administration at a dosage of 6 mg/kg, under fed or fasted conditions, or intravenous administration of 3 mg/kg, blood samples were collected up to 35 days after treatment. Lotilaner blood concentrations were measured using a validated liquid chromatography/tandem mass spectrometry method. Pharmacokinetic parameters were calculated by non-compartmental analysis. In addition, in vivo enantiomer stability of lotilaner was evaluated in a separate bioanalytical study. RESULTS: Following oral administration in fed cats, lotilaner was readily absorbed and peak blood concentrations reached within four hours. The terminal half-life was 33.6 days. Food enhanced the absorption, providing close to 100% oral bioavailability and reduced the inter-individual variability. Following intravenous administration, lotilaner had a low clearance of 0.13 l/kg/day, large volumes of distribution V(z) and V(ss) of 5.34 and 5.37 l/kg, respectively and a terminal half-life of 28.7 days. In addition, there was no in vivo racemization of lotilaner. CONCLUSIONS: The pharmacokinetic properties of lotilaner administered orally as a flavoured chewable tablet (Credelio(TM)) were studied in detail. With a T(max) of 4 h and a terminal half-life of 33.6 days under fed conditions, lotilaner provides a rapid onset of flea and tick killing activity with consistent and sustained efficacy for at least one month in cats. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13071-018-2966-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-07-13 /pmc/articles/PMC6044034/ /pubmed/30001724 http://dx.doi.org/10.1186/s13071-018-2966-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Toutain, Céline E.
Seewald, Wolfgang
Jung, Martin
Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats
title Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats
title_full Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats
title_fullStr Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats
title_full_unstemmed Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats
title_short Pharmacokinetics of lotilaner following a single oral or intravenous administration in cats
title_sort pharmacokinetics of lotilaner following a single oral or intravenous administration in cats
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044034/
https://www.ncbi.nlm.nih.gov/pubmed/30001724
http://dx.doi.org/10.1186/s13071-018-2966-6
work_keys_str_mv AT toutaincelinee pharmacokineticsoflotilanerfollowingasingleoralorintravenousadministrationincats
AT seewaldwolfgang pharmacokineticsoflotilanerfollowingasingleoralorintravenousadministrationincats
AT jungmartin pharmacokineticsoflotilanerfollowingasingleoralorintravenousadministrationincats